105834-28-4

Upstream product

• 533-31-3 Sesamol 
• 297748-84-6 (3R,4S)-methyl-1-benzyl-4-(4-fluorophenyl)-2-oxopiperidine-3-carboxylate 
• 188869-25-2 (-)-trans-1-benzyl-3-hydroxymethyl-4-(4-fluorophenyl)piperidine 
• 177966-75-5 (4S)-1-(phenylmethyl)-4-(4-fluorophenyl)piperidin-2-one 
• 216690-16-3 (3R)-methyl hydrogen 3-(4-fluorophenyl)pentane-1,5-dioate 
• 216690-15-2 dimethyl 3-(4-fluorophenyl)glutarate 
• 297748-83-5 (S)-3-(4-Fluoro-phenyl)-5-hydroxy-pentanoic acid methyl ester 
• 459-57-4 4-fluorobenzaldehyde 

Downstream Products

• 130855-30-0 (+)-(3R,4S)-trans-3-[(1,3-Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine hydrochloride 
• 130855-30-0 (+)-paroxetin 

Relevant academic research and scientific papers

N-benzylpiperidine and tetrahydropyridine derivatives

A process is disclosed for the preparation of compounds of the formula (I), which compounds are useful as intermediates for the preparation of paroxetine of formula(V).

Asymmetric synthesis of (-)-paroxetine using PLE hydrolysis

(-)-Paroxetine hydrochloride was produced asymmetrically in seven steps starting from 4-fluoro-benzaldehyde. The stereocenter at C-4 was initially set through desymmetrization of glutaric acid bis methyl ester 4 by PLE hydrolysis. A unique one-pot reduction-alkylation procedure was then developed to provide entry to lactam 2 with the appropriate absolute stereochemistry. (C) 2000 Elsevier Science Ltd.